Technical specification for clinical diagnosis and treatment of human parvovirus B19 infection in kidney transplant recipients (2022 edition)
10.3969/j.issn.1674-7445.2022.02.001
- VernacularTitle:肾移植受者人类微小病毒B19感染临床诊疗技术规范（2022版）
- Collective Name:Branch of Organ Transplantation of Chinese Medical Association;National Kidney Transplantation Quality Control Center
- Publication Type:Research Article
- Keywords:
Human parvovirus B19 (HPV-B19);
Pure red cell aplasia (PRCA);
Erythropoietin (EPO);
Signal transducer and activator of transcription (STAT);
Anti-human T lymphocyte immunoglobulin (ALG);
Intravenous immunoglobulin (IVIG);
Next generation sequencing (NGS);
Cidofovir;
Hydroxyurea;
Foscarnet sodium
- From:
Organ Transplantation
2022;13(2):135-
- CountryChina
- Language:Chinese
-
Abstract:
Long-term use of immunosuppressant in kidney transplant recipients leads to poor immune function and infection with various pathogens. In recent years, along with the advancement of detection technique of human parvovirus B19 (HPV-B19) infection and the increasing quantity of kidney transplantation, the infection rate of HPV-B19 after kidney transplantation has been elevated year by year, becoming one of the major causes of pure red cell aplasia (PRCA), affecting the recovery of renal allograft function, and even leading to the injury or poor prognosis of renal allograft. To further standardize the diagnosis and treatment of HPV-B19 infection in kidney transplant recipients, Branch of Organ Transplantation of Chinese Medical Association and National Kidney Transplantation Quality Control Center jointly organized experts to formulate the clinical diagnosis and treatment specification for HPV-B19 infection after kidney transplantation from the perspectives of etiology, epidemiological characteristics, clinical manifestations, diagnosis, prevention, treatment, existing problems and prospects of HPV-B19, aiming to provide guidance for standardized prevention and treatment of HPV-B19 infection post-kidney transplantation in China.
